Remdesivir and tixagevimab plus cilgavimab for treating COVID-19

  • Technology appraisal guidance
  • TA971
  • Published: 

Resource impact template

NICE has produced a resource impact template that incorporates the following technology appraisal guidance for COVID-19:

  • Remdesivir and tixgevimab plus cilgavimab for treating COVID-19 (2024) NICE technology appraisal guidance 971
  • Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (2023) NICE technology appraisal guidance 878

 

 

 

This page was last updated: